Tonix Pharmaceuticals names CEO's son as strategy chief

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has appointed George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation, effective October 30, 2026, according to a company statement.

Dr. Lederman is the son of Seth Lederman, M.D., Tonix's President, Chief Executive Officer, and Chairman. The appointment was reviewed and approved by the independent members of the company's Board of Directors and Audit Committee under its related party transactions policy, with compensation reviewed and approved by independent board members and the Compensation Committee.

In the role, Dr. Lederman will lead artificial intelligence initiatives aimed at improving operational efficiency and managing costs. He will also oversee business development efforts, including evaluating potential partnerships and licensing opportunities related to the company's clinical programs.

Dr. Lederman joins Tonix from Aliaxis, a global industrial group, where he most recently served as Vice President of Global Strategy. During his four-year tenure there, the company divested six assets, acquired four companies, and implemented a 10% enterprise-wide fixed cost reduction.

Prior to Aliaxis, Dr. Lederman was an Associate Partner at McKinsey & Company, where he helped build the firm's digitization practice and advised clients on machine learning, advanced analytics, and AI applications.

He holds a Ph.D. in Advanced Infrastructure Systems from Carnegie Mellon University, master's degrees in Electrical and Computer Engineering and Civil and Environmental Engineering from Carnegie Mellon, and a bachelor's degree in Civil Engineering from Princeton University. He was a National Science Foundation Graduate Research Fellow.

You May Also Be Interested In

• Anthropic PBC: adjusted operating income increased for the three months ended September 30, 2026 to $2.5 billion
• Propanc Biopharma releases preclinical data on PRP in pancreatic cancer
• Neo-Concept International completes 8-for-1 share consolidation on Nasdaq